The lead time and overdetection associated with prostate-specific antigen (PSA) screening, and generational improvements in all-cause mortality, make prostate cancer outcome studies from the pre-PSA era difficult to interpret in a contemporary setting. This evidence concerns the gene KLK3 and prostate carcinoma.